Edition:
India

Akebia Therapeutics Inc (AKBA.OQ)

AKBA.OQ on NASDAQ Stock Exchange Global Market

15.25USD
2:29am IST
Change (% chg)

$0.20 (+1.33%)
Prev Close
$15.05
Open
$15.15
Day's High
$15.40
Day's Low
$14.95
Volume
76,845
Avg. Vol
155,828
52-wk High
$20.25
52-wk Low
$8.26

Chart for

About

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $894.46
Shares Outstanding(Mil.): 47.15
Dividend: --
Yield (%): --

Financials

BRIEF-Akebia Therapeutics reports Q3 loss per share $0.49

* Akebia Therapeutics announces third quarter 2017 financial results

09 Nov 2017

BRIEF-Invirsa secures seed financing to develop new approach

* Invirsa secures seed financing to develop new approach to treating common infectious diseases that affect millions annually Source text for Eikon: Further company coverage:

07 Nov 2017

Insider trading suspect out of U.S. jail as judge weighs 'Jekyll & Hyde' risk

BOSTON, Oct 12 A former Akebia Therapeutics Inc employee accused of insider trading was released from jail on Thursday despite a judge's concern that the man's "Dr. Jekyll and Mr. Hyde" tendencies could lead him to violate his bail conditions.

13 Oct 2017

Ex-Akebia employee suspected of insider trading re-arrested

BOSTON, Sept 22 A former Akebia Therapeutics Inc employee accused of insider trading was re-arrested on Friday after violating a bail condition as a prosecutor who once called him "increasingly unhinged" said he would seek the man's detention pending trial.

23 Sep 2017

Ex-Akebia employee faces losing bail in insider trading case

BOSTON, July 20 A former Akebia Therapeutics Inc employee accused of insider trading faced the growing possibility of having his bail revoked as a U.S. prosecutor argued on Thursday that he posed a flight risk and was growing "increasingly unhinged."

21 Jul 2017

BRIEF-Muneer Satter reports 6.48 pct stake in Akebia Therapeutics

* Muneer Satter reports 6.48 percent stake in Akebia Therapeutics Inc as of July 5 - SEC filing

15 Jul 2017

BRIEF-Akebia Therapeutics announces proposed public offering of common stock

* Akebia Therapeutics announces proposed public offering of common stock

29 Jun 2017

Earnings vs. Estimates